PharmaCyte Biotech Inc (PMCB)

[Peacefulwendy]

However, as you shared with us a few months back, Dr Von Hoff and TD2 have a more progressive trial design for Phase 1, article link below. Also, TD2 has recently started using new technology to provide real-time patient feedback. TD2's entire focus is getting drugs to market more quickly. It is important to keep all information relevant to what is happening today with PharmaCyte and it's partners.


TD2 and Navigating Cancer Partner to Bring Patient-Reported Outcomes to Clinical Trials Through a Cutting-Edge Mobile Application

Leading patient engagement and mobile care management solution and precision oncology CRO partner to revolutionize patient engagement in clinical trials
Business Wire TD2

April 20, 2015 12:01 AM
SCOTTSDALE, Ariz. & SEATTLE--(BUSINESS WIRE)--

TD2, the precision oncology CRO, and Navigating Cancer, the leading web-based patient care and engagement solution for oncology clinics, today announced a partnership to improve the engagement of patients in clinical trials and bring patient-reported outcomes to the clinical trials process.

The integration with Navigating Cancer’s mobile care management solution will allow patients participating in TD2-managed clinical trials to record adherence and report how they are feeling in real time through a simple-to-use mobile application. This information will be provided to TD2’s participating oncology trial sites to enhance the care of patients enrolled in clinical studies. This access to patient-reported experiences on emerging therapies will provide biotechnology and pharmaceutical companies with new insights that could be used to improve trial designs, develop unique clinical trial endpoints and add value in reimbursement decisions.

“Real-time patient-reported data using Navigating Cancer’s mobile solution is an important component of the TD2 clinical trial process,” said TD2 CEO Stephen Gately, Ph.D. “ This data will be used to support more efficient patient-focused clinical trial designs, and to potentially identify regulatory opportunities for new medicines that improve patient symptoms and functional abilities.”

"As a company dedicated to improving health outcomes through patient engagement, we believe that providing patients in clinical trials with a convenient, mobile means of reporting their own experiences on an investigative therapy in real time will be a game-changer for patient-centered drug development.” said Gena Cook, CEO of Navigating Cancer. “We are excited to partner with TD2 to ensure that patient’s experiences are reflected in health outcomes.”

About Navigating Cancer

Navigating Cancer is the leading patient engagement platform and mobile care management solution for cancer centers across the United States. For patients, Navigating Cancer provides a single, comprehensive hub that operates with any electronic health record system, enabling them to stay seamlessly informed and engaged in their own care across multiple clinics, caregivers and geographies. For providers, Navigating Cancer offers a convenient, scalable solution for care management and engagement, a vital tool in the evolution to value-based medicine, and an agile means of satisfying current requirements for Meaningful Use, Commission on Cancer and new payment reform models. For more information, visit: https://www.navigatingcancer.com

http://www.medelis.com/clinical-cancer-research-abstracts/complete-phase-ib-trial-design/

http://finance.yahoo.com/news/td2-navigating-cancer-partner-bring-040100983.html;_ylt=AwrTceOoCrlVIIQA5_wnnIlQ;_ylu=X3oDMTByM3V1YTVuBGNvbG8DZ3ExBHBvcwMzBHZ0aWQDBHNlYwNzcg--